---
title: "GI Stromal Tumors"
format: 
  revealjs:
    slide-number: c/t
    width: 1600
    height: 900
    logo: "atriumlogo.jpg"
    footer: "[GI Surgical Oncology Talks](https://gisurgonc.github.io/talks/)"
    #css: ["theme/theme.css"]
    theme: default
      
    echo: false
editor: visual
bibliography: zotero.bib
---

## ACOSOG ZZ9001

GIST Tumors \>3cm randomized:

-   1 year of imatinib 40mg
-   Observation

Recurrence-free survival 98% vs 83%

No significant difference at 6 years

*Imatinib may simply delay recurrences*

::: aside
Ref
:::

## SSG SVII

High-risk GIST randomized:

-   1 year of imatinib 400mg
-   3 year of imatinib 400mg

5-year Recurrence-free survival 48% vs 66%

5-year Overall Survival 82% vs 92%

::: aside
Ref
:::

## Mutational Testing

Genetic mutations can predict response to imatinib [^1]

[^1]: Meheran JCO 2017

## Positive Margins

::: aside
Gronchi JAMA Surg 2020
:::

## Imatinib 1yr vs 3 yr

::: aside
Joensuu JAMA Oncology 2020
:::

## Wild-Type GIST

-   SDH-Deficient
    -   SDHx mutation
    -   SDH wild-type
    -   Associated with Carney-Stratakis syndrome
-   No SDH Deficiency
    -   NF1-GIST
    -   Sporadic Wild-Type GIST

::: aside
Weldon JCS 2017
:::

## NF1-associated GIST

-   Multicentric (33%)
-   Median age 46
-   Small bowel \>\> Duodenum \>\> Stomach

::: aside
Weldon JCS 2017
:::

## Recurrence Risk

+-------------------+----------+--------------+
| Risk              | Size     | Mitotic Rate |
+===================+==========+==============+
| Very Low Risk     | \<2cm    | \<5          |
+-------------------+----------+--------------+
| Low Risk          | 2-5cm    | \<5          |
+-------------------+----------+--------------+
| Intermediate Risk | \<5cm\   | 6-10\        |
|                   | 5-10cm   | \<5          |
+-------------------+----------+--------------+
| High Risk         | \>5cm\   | \>5 /50\     |
|                   | \>10cm\  | Any\         |
|                   | Any size | \>10         |
+-------------------+----------+--------------+

: Mitotic rate per 50 hpf

::: aside
Fletcher Int J Surg Pathol 10:81 2022
:::

## AFIP Risk Classification

::: aside
Miettinen Lasota Seminars in Diagnostic Pathology 2006:23:70-83
:::

# Orientation Manual

{{< qrcode https://gisurgonc.github.io/orientation width=500 height=500 >}}

# References
